$43.25
1.10% yesterday
NYSE, Nov 25, 10:10 pm CET
ISIN
NL0012169213
Symbol
QGEN

QIAGEN NV Stock price

$43.25
+1.70 4.09% 1M
-0.48 1.10% 6M
-1.52 3.40% YTD
+1.40 3.36% 1Y
-13.00 23.11% 3Y
+0.13 0.29% 5Y
+17.60 68.61% 10Y
NYSE, Closing price Mon, Nov 25 2024
+0.47 1.10%
ISIN
NL0012169213
Symbol
QGEN
Sector

Key metrics

Market capitalization $9.59b
Enterprise Value $10.03b
P/E (TTM) P/E ratio 107.13
EV/FCF (TTM) EV/FCF 21.65
EV/Sales (TTM) EV/Sales 5.10
P/S ratio (TTM) P/S ratio 4.88
P/B ratio (TTM) P/B ratio 2.72
Revenue growth (TTM) Revenue growth 0.62%
Revenue (TTM) Revenue $1.97b
EBIT (operating result TTM) EBIT $471.97m
Free Cash Flow (TTM) Free Cash Flow $463.48m
Cash position $1.48b
EPS (TTM) EPS $0.40
P/E forward 96.54
P/S forward 4.85
EV/Sales forward 5.07
Short interest 2.10%
Show more

Is QIAGEN NV a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 6,883 stocks worldwide.

QIAGEN NV Stock Analysis

Unlock Scores for Free

Analyst Opinions

23 Analysts have issued a QIAGEN NV forecast:

14x Buy
61%
9x Hold
39%

Analyst Opinions

23 Analysts have issued a QIAGEN NV forecast:

Buy
61%
Hold
39%

Financial data from QIAGEN NV

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Sep '24
+/-
%
1,966 1,966
1% 1%
100%
- Direct Costs 735 735
0% 0%
37%
1,231 1,231
1% 1%
63%
- Selling and Administrative Expenses 359 359
5% 5%
18%
- Research and Development Expense 191 191
3% 3%
10%
681 681
6% 6%
35%
- Depreciation and Amortization 209 209
0% 0%
11%
EBIT (Operating Income) EBIT 472 472
8% 8%
24%
Net Profit 93 93
72% 72%
5%

In millions USD.

Don't miss a Thing! We will send you all news about QIAGEN NV directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

QIAGEN NV Stock News

Neutral
Seeking Alpha
19 days ago
Qiagen N.V. (NYSE:QGEN ) Q3 2024 Earnings Conference Call November 7, 2024 9:30 AM ET Company Participants John Gilardi - VP, Head of Corporate Communications and IR Thierry Bernard - CEO Roland Sackers - CFO Conference Call Participants Patrick Donnelly - Citi Odysseas Manesiotis - Berenberg Matt Sykes - Goldman Sachs Doug Schenkel - Wolfe Research Aisyah Noor - Morgan Stanley Michael Ryskin -...
Positive
Reuters
20 days ago
Qiagen reported a rise in third-quarter revenue on Wednesday, owing to strong sales of its diagnostic devices.
AD HOC NEWS
21 days ago
Der Labordienstleister Qiagen NL0012169213 hat im vergangenen Quartal von einer anziehenden Nachfrage nach Diagnostiklösungen profitiert und seinen Umsatz überraschend stark gesteigert.
More QIAGEN NV News

Company Profile

QIAGEN NV is a holding company, which engages in the provision of sample and assay technology to transform biological samples into valuable molecular insights. It offers bioinformatics, molecular diagnostics, next-gen sequencing, and genomic services. The company was founded by Detlev H. Riesner and Metin Colpan on April 29, 1996 and is headquartered in Venlo, the Netherlands.

Head office Netherlands
CEO Thierry Bernard
Employees 5,967
Founded 1996
Website www.qiagen.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today